OTHER NEWS - Nov. 29, 1994
- Share via
Biotech Firm Strikes Deal With Bayer: Arris Pharmaceutical Corp. said Bayer AG will invest up to $70 million as part of an agreement to jointly develop anti-inflammatory drugs. Under the agreement, Arris, a South San Francisco biotechnology company, will receive royalties and Bayer, a Germany-based drug company, will receive worldwide manufacturing and marketing rights on any drugs that they develop together. Arris will receive an initial payment and additional funds as it reaches certain milestones.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
